CA3192868A1 - Novel aminopyridines and their use in treating cancer - Google Patents
Novel aminopyridines and their use in treating cancerInfo
- Publication number
- CA3192868A1 CA3192868A1 CA3192868A CA3192868A CA3192868A1 CA 3192868 A1 CA3192868 A1 CA 3192868A1 CA 3192868 A CA3192868 A CA 3192868A CA 3192868 A CA3192868 A CA 3192868A CA 3192868 A1 CA3192868 A1 CA 3192868A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- nhc
- nr2r2
- compound
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ768245 | 2020-09-24 | ||
| NZ76824520 | 2020-09-24 | ||
| PCT/IB2021/058707 WO2022064430A1 (en) | 2020-09-24 | 2021-09-24 | Novel aminopyridines and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3192868A1 true CA3192868A1 (en) | 2022-03-31 |
Family
ID=80844550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3192868A Pending CA3192868A1 (en) | 2020-09-24 | 2021-09-24 | Novel aminopyridines and their use in treating cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230365559A1 (https=) |
| EP (1) | EP4217357A4 (https=) |
| JP (1) | JP7839786B2 (https=) |
| CN (1) | CN116669725A (https=) |
| AU (1) | AU2021346954A1 (https=) |
| CA (1) | CA3192868A1 (https=) |
| WO (1) | WO2022064430A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024191996A1 (en) * | 2023-03-13 | 2024-09-19 | Incyte Corporation | Bicyclic ureas as kinase inhibitors |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20230057A (es) | 2020-07-02 | 2023-08-15 | Incyte Corp | Compuestos tríciclicos de urea como inhibidores de jak2 v617f |
| AU2023235313A1 (en) | 2022-03-17 | 2024-10-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011021678A1 (ja) * | 2009-08-21 | 2011-02-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| CA2902858A1 (en) * | 2013-02-28 | 2014-09-04 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
| ME03336B (me) * | 2013-03-12 | 2019-10-20 | Vertex Pharma | Inhibitori dnk-pk |
| JP6883653B2 (ja) | 2016-12-20 | 2021-06-09 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用 |
| JP7202315B2 (ja) * | 2017-05-26 | 2023-01-11 | キャンサー・リサーチ・テクノロジー・リミテッド | ベンズイミダゾロン由来のｂｃｌ６阻害剤 |
| TWI820146B (zh) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
| GB201819126D0 (en) * | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
| WO2020140054A1 (en) * | 2018-12-28 | 2020-07-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
-
2021
- 2021-09-24 AU AU2021346954A patent/AU2021346954A1/en active Pending
- 2021-09-24 CA CA3192868A patent/CA3192868A1/en active Pending
- 2021-09-24 JP JP2023518938A patent/JP7839786B2/ja active Active
- 2021-09-24 WO PCT/IB2021/058707 patent/WO2022064430A1/en not_active Ceased
- 2021-09-24 EP EP21871799.9A patent/EP4217357A4/en active Pending
- 2021-09-24 US US18/246,100 patent/US20230365559A1/en active Pending
- 2021-09-24 CN CN202180070775.4A patent/CN116669725A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024191996A1 (en) * | 2023-03-13 | 2024-09-19 | Incyte Corporation | Bicyclic ureas as kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023542548A (ja) | 2023-10-10 |
| WO2022064430A1 (en) | 2022-03-31 |
| EP4217357A4 (en) | 2024-11-06 |
| EP4217357A1 (en) | 2023-08-02 |
| AU2021346954A9 (en) | 2024-02-08 |
| JP7839786B2 (ja) | 2026-04-02 |
| CN116669725A (zh) | 2023-08-29 |
| US20230365559A1 (en) | 2023-11-16 |
| AU2021346954A1 (en) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11345711B2 (en) | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | |
| TWI891649B (zh) | 作為cd38抑制劑之雜雙環醯胺 | |
| KR100697746B1 (ko) | 키나제 저해제로서의 디아제피노인돌 유도체 | |
| RU2470934C1 (ru) | Новое трициклическое производное или его фармацевтически приемлемые соли, способ их получения и содержащая их фармацевтическая композиция | |
| CA2884848C (en) | Benzamide and heterobenzamide compounds | |
| AU2021200884A1 (en) | MK2 inhibitors and uses thereof | |
| US20110166169A1 (en) | Novel hsp90 inhibitory carbazole derivatives, compositions containing same and use thereof | |
| CA3192868A1 (en) | Novel aminopyridines and their use in treating cancer | |
| US11345710B2 (en) | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof | |
| WO2002024701A2 (en) | Substituted azepino[4,5b)indole derivatives | |
| CN113939292B (zh) | Btk及其突变体的抑制剂 | |
| US11952377B2 (en) | Quinolines and azaquinolines as inhibitors of CD38 | |
| EP1896472A1 (de) | Alpha-carboline als cdk-1 inhibitoren | |
| US20220363689A1 (en) | Inhibitor of btk and mutants thereof | |
| US11547703B2 (en) | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | |
| JP2011513471A (ja) | チアゾリル−ジヒドロ−インダゾール | |
| CN112041319B (zh) | 三唑、咪唑和吡咯稠合的哌嗪衍生物及其作为mGlu5受体的调节剂的应用 | |
| HK40129150A (en) | Azaquinolines as inhibitors of cd38 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250311 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250311 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250311 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250916 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250916 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250918 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250918 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250918 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251027 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251119 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251119 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251119 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251119 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251119 |